All Assays articles – Page 3
-
ArticleAdvancing disease biomarker research with EV multiplex profiling
Vanitha Margan, Global Product Manager for Bio-Plex Multiplex Immunoassays at Bio-Rad Laboratories, reveals how multiplexing is being used to realise the full potential of extracellular vesicles in disease monitoring.
-
ArticleTackling the organ shortage through vascular bioengineering
Frontier Bio’s vascular bioengineering research connects tissue modelling with graft development to advance regenerative medicine and drug discovery.
-
ArticleTransforming central labs with automation and AI: setting new standards for modern trials
Demands on central laboratories are consistently increasing, heightening the challenge to deliver operational excellence and the highest standard of scientific integrity with both speed and agility. ICON Laboratories is transforming the way we leverage data and intelligent operational models to meet evolving trial needs.
-
ArticleMaking science run at the speed of thought: the reality of AI in drug discovery – Part 1
Everyone talks about AI speeding up drug discovery, but Eric Ma explains why, without clean data and statistical discipline, it can actually do the opposite.
-
ArticleDeep data not big data
Bigger isn’t always better. In drug discovery, Dr Michael Ritchie argues that the future belongs not to those with the most data, but to those who understand its biological depth.
-
ArticleAI and the future of biomarker analysis in early R&D
AI is transforming biomarker analysis in early drug discovery, revealing hidden biological patterns that improve target discovery, patient selection and trial design for more precise and predictive R&D.
-
ArticleWhy first-void urine could potentially change the future of HPV screening
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
-
ArticleInside ELRIG Drug Discovery 2025: automation, AI and human-relevant models
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
-
NewsNuclera expands into Australasia with Solve Scientific partnership
Cambridge-based biotech firm Nuclera has partnered with Solve Scientific Australia to expand access to its eProtein Discovery™ System across Australia and New Zealand.
-
ReportLab Automation: Where Discovery Scales
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
-
NewsNew blood test detects Alzheimer’s years before symptoms
Scientists have developed two rapid and affordable blood tests that can detect early markers of Alzheimer’s disease – potentially decades before symptoms appear.
-
ArticleWhat’s changing in cancer drug discovery – and why it matters now
Take part in a live Q&A with oncology experts as they explore the scientific advances driving cancer drug discovery.
-
ArticleWhen chemistry corrects biology: the deuterated return of a MET inhibitor
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
-
ArticleFrom wild fungi to faster drug discovery
Nature’s pharmacy has yielded half of today’s medicines, yet most of its potential remains untapped. AI is now changing how quickly new therapies can be found.
-
NewsEnzyme PapB could boost diabetes and obesity peptide drugs
Researchers have discovered an enzyme, PapB, that can ‘tie off’ therapeutic peptides into stable rings, which could help improve GLP-1 drugs for diabetes and obesity – making them more effective and longer lasting.
-
ArticleSPNS1 mutations reveal new lysosomal lipid recycling pathway
Scientists have linked rare mutations in SPNS1 to a previously unknown lipid recycling pathway in lysosomes, revealing how faulty fat processing can trigger muscle and liver disease.
-
ArticleThe predictive validity crisis: Pharma’s productivity paradox – Part I
Drug discovery now costs 100 times more per FDA-approved drug than in 1950, despite vast advances in biology and computing. The core problem is the collapse of predictive validity in preclinical models, which sits at the heart of pharma’s productivity paradox.
-
NewsHIV antibody 04_A06 almost neutralises all strains
A newly discovered antibody, 04_A06, has shown unprecedented effectiveness against HIV, neutralising 98.5 percent of tested strains and permanently suppressing the virus in humanised mice.
-
ArticleAdvancing gene editing: the role of lipid nanoparticles in CRISPR delivery
CRISPR therapies depend on delivery and lipid nanoparticles are emerging as a more flexible and scalable option than viral vectors.
-
NewsScientists track amyloid plaques in living mice for first time
A new fibre-optic method lets researchers monitor amyloid plaque buildup in living, freely moving mice – offering a minimally invasive way to track Alzheimer’s disease progression and test potential therapies.